Regulatory Alignment Of UK With EU Post-Brexit Seen As Critical
Executive Summary
Retain high-quality regulatory capability and the innovative leadership of the UK medicines agency, align with the EU and don’t build a stand-alone regulatory system. Those are some of the recommendations in the new and wide-ranging industry-led Life Sciences Industrial Strategy relating to the future, post-Brexit regulation of medicines in the UK.
You may also be interested in...
Merck's UK Proposal: What's Attracting the US Giant To London For Innovation?
Merck & Co. will build a new innovation hub in London – an act described by the UK government as a major strategic investment – despite widespread Brexit ambiguity and a potentially unstable economic situation ahead for the soon-to-be ex-EU nation.
Yet Another UK Call For Views On What Brexit Means For Pharma, Regulation & Health
Another inquiry investigation into the consequences of Brexit in the life sciences area has been launched, this time by the UK House of Commons health committee. Stakeholders are asked to comment on issues like the impact on the regulation of medicines and medical devices, how to ensure continued access to medicines, and whether transitional arrangements will be needed.
UK Life Science Strategy Urges Adoption Of Accelerated Access Review, As Govt Prepares Response
A set of proposals in the recently published Life Sciences Industrial Strategy, aimed at improving the way new products are identified and made available under the NHS, reiterates ideas contained in the 2016 Accelerated Access Review. The government says it will respond to the review shortly.